Pautas E - Search Results

1

Human NK cells display major phenotypic and functional changes over the life span.

Le Garff-Tavernier M, Béziat V, Decocq J, Siguret V, Gandjbakhch F, Pautas E, Debré P, Merle-Beral H, Vieillard V. Le Garff-Tavernier M, et al. Among authors: pautas e. Aging Cell. 2010 Aug;9(4):527-35. doi: 10.1111/j.1474-9726.2010.00584.x. Epub 2010 May 10. Aging Cell. 2010. PMID: 20477761 Free article.

2

Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.

Siguret V, Pautas E, Février M, Wipff C, Durand-Gasselin B, Laurent M, Andreux JP, d'Urso M, Gaussem P. Siguret V, et al. Among authors: pautas e. Thromb Haemost. 2000 Nov;84(5):800-4. Thromb Haemost. 2000. PMID: 11127859

3

[Monitoring of tinzaparin in a ten day treatment dose in elderly patients].

Pautas E, Siguret V, d'Urso M, Laurent M, Gaussem P, Février M, Durand-Gasselin B. Pautas E, et al. Rev Med Interne. 2001 Feb;22(2):120-6. doi: 10.1016/s0248-8663(00)00301-5. Rev Med Interne. 2001. PMID: 11234669 Clinical Trial. French.

4

Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients.

Pautas E, Gouin I, Bellot O, Andreux JP, Siguret V. Pautas E, et al. Drug Saf. 2002;25(10):725-33. doi: 10.2165/00002018-200225100-00005. Drug Saf. 2002. PMID: 12167068 Clinical Trial.

5

[Oral anticoagulants in the elderly].

Debray M, Pautas E, Couturier P, Franco A, Siguret V. Debray M, et al. Among authors: pautas e. Rev Med Interne. 2003 Feb;24(2):107-17. doi: 10.1016/s0248-8663(02)00020-6. Rev Med Interne. 2003. PMID: 12650892 Review. French.

6

[Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients].

Siguret V, Gouin I, Golmard JL, Geoffroy S, Andreux JP, Pautas E. Siguret V, et al. Among authors: pautas e. Rev Med Interne. 2004 Apr;25(4):271-4. doi: 10.1016/j.revmed.2003.11.006. Rev Med Interne. 2004. PMID: 15050794 Clinical Trial. French.

7

Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between June 2002 and March 2004.

Siguret V, Pautas E, Gouin I. Siguret V, et al. Among authors: pautas e. Curr Opin Pulm Med. 2004 Sep;10(5):366-70. doi: 10.1097/01.mcp.0000136900.91924.3d. Curr Opin Pulm Med. 2004. PMID: 15316433 Review.

8

Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen.

Siguret V, Gouin I, Debray M, Perret-Guillaume C, Boddaert J, Mahé I, Donval V, Seux ML, Romain-Pilotaz M, Gisselbrecht M, Verny M, Pautas E. Siguret V, et al. Among authors: pautas e. Am J Med. 2005 Feb;118(2):137-42. doi: 10.1016/j.amjmed.2004.07.053. Am J Med. 2005. PMID: 15694897 Clinical Trial.

9

Safety profile of different low-molecular weight heparins used at therapeutic dose.

Gouin-Thibault I, Pautas E, Siguret V. Gouin-Thibault I, et al. Among authors: pautas e. Drug Saf. 2005;28(4):333-49. doi: 10.2165/00002018-200528040-00005. Drug Saf. 2005. PMID: 15783242 Review.

10

Haemorrhagic complications of vitamin k antagonists in the elderly: risk factors and management.

Pautas E, Gouin-Thibault I, Debray M, Gaussem P, Siguret V. Pautas E, et al. Drugs Aging. 2006;23(1):13-25. doi: 10.2165/00002512-200623010-00002. Drugs Aging. 2006. PMID: 16492066 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

107 results

Search Page

Filters